It is believed that ATRA therapeutic action in APL involves degradation of PML-RAR [7, 49], which releases the suppressive effect exerted by the fusion protein on the product of the intact RARA allele, RARα [2, 3]. The gene discussed is RARA; the disease is acute promyelocytic leukemia.